350 rub
Journal Technologies of Living Systems №4 for 2011 г.
Article in number:
DIAGNOSTIC AND PROGNOSTIC VALUE OF P16INK4A IN PATIENTS WITH CERVICAL INTRAEPITHELIAL NEOPLASIA AND EARLY CERVICAL CANCER
Authors:
L.I. Korolenkova
Abstract:
Persistent HPV-infection is the main etiological factor of cervical intraepithelial neoplasia (CIN) and cervical cancer. Considering HPV-infection to be very widespread (30?40 % of female population), its outcome to CIN I and later to CIN II?III and cervical cancer is relatively rare. Regression and stabilization of the process are also possible. There is a need for additional studies allowing stratification of women with HPV-infection and CIN regarding risk of progression to CIN III/carcinoma in citu (CIS) and invasive cancer. The major difficulty represents the groups of pa-tients with cytology results ASCUS and LSIL, as well as histologicaly verified CIN II, as they consist of women with both productive and transforming infection. One of the possible approaches is the use of markers of transforming infection, primarily p16INK4a.
p16INK4a ? cyclin-dependent kinase inhibitor - may be seen as the marker of conversion of productive HPV-infection to transforming stage that clinically corresponds to progression of low-grade neoplasias (CIN I) to high-grade (CIN II-III). This confirms the significant elevation of p16 expression gain in CIN II tissue samples. P16INK4a seems to be especially important in CIN II pa-tients, because not all CIN II potentially progress to CIN III showing the certain rate of spontaneous regression. P16INK4a may be useful for triage of HPV-infected women revealed by cytological and virological screening stages. P16INK4a immunocytochemical staining may serve as a valuable tool in case of viral load persistence after conservative treatment modalities as it helps to differentiate persisting HPV-infection without CIN and CIN progression or recurrence. Taking into account the follow-up longevity of patients treated for high-grade CIN (up to 30 years) P16INK4a may play its role in defining individual outcome and algorithm of follow-up.
Pages: 38-43
References
- Роговская С.И. Папилломовирусная инфекция у женщин и патология шейки матки. М.: ГЭОТАР-Медиа. 2008.
- Walboomers J.M., Jacobs M.V., Manos M.M. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide // J. Pathol. 1999. V. 189(1). P.12 - 9.
- www.who.int/hpvcentre
- Petry K.U. Textbook of Gynecological Oncology. Güneş Publishing. 2009. P. 63 - 66.
- Naucler P., Ryd W., Törnberg S. et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening // J. Natl. Cancer. Inst. 2009. V. 101(2). P. 88 - 99.
- Ullal A., Roberts M, Bulmer J.N. et al.The role of cervical cytology and colposcopy in detecting cervical glandular neoplasia // Cytopathology. 2008. V. 20(6). P.359 - 366.
- Nassar A., O'Reilly K., Cohen C., Siddiqui M.T. Comparison of p16(INK4A) and Hybrid Capture(R) 2 human papillomavirus testing as adjunctive tests in liquid - based gynecologic SurePathtrade mark preparations // Diagn. Cytopathol. 2008. V. 36(3). P. 142 - 148.
- БаггишМ. Кольпоскопия.М.:Практика. 2008.
- Vinokurova S., Wentzensen N., Kraus I., Klaes R., Driesch C., Melsheimer P.et al. Type dependent integration frequency of human papillomavirus genomes in cervical lesions // Cancer. Res. 2008. V. 68. P. 307 - 13.
- Clarke B., Chetty R. Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix // Gynecol. Oncol. 2001. V. 82(2). P. 238 - 46.
- Masumoto N., Fujii T., Ishikawa M.et al. P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix // Hum. Pathol. 2003. V. 34(8). P. 778 - 83.
- Tota J., Franco E.L. HPV infection and cervical cancerogenesis: epidemiology and prevention // Textbook of Gynecological Oncology // Güneş Publishing. 2009. P. 49 - 52.
- Wentzensen N., von Knebel D.M.Biomarkers in cervical cancer screening // Dis. Markers. 2007. V. 23. P. 15 - 30.
- Gonzalez S.L., Stremlau M., He X. et al. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7 // J. Virol. 2001. V. 75. P. 7583 - 91.
- Lambert A.P., Anschau F., and Schmitt V.M. p16INK4A expression in cervical premalignant and malignant lesions // Exp. Mol. Pathol. 2006. V. 80. P. 192 - 6.
- Queiroz C., Silva T.C., Alves V.A., Villa L.L., Costa M.C. Travassos AG et al. P16(INK4a) expression as a potential prognostic marker in cervical pre - neoplastic and neoplastic lesions // Pathol. Res. Pract. 2006. V. 202. P. 77 - 83.
- Ishikawa M., Fujii T., Saito M. et al. Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia // Int. J. Gynecol. Cancer. 2006 Jan - Feb. V. 16(1). P. 347 - 53.
- Benevolo M., Mottolese M., Marandino F. et al. Immunohistochemical expression of p16(INK4a) is predictive of HR - HPV infection in cervical low - grade lesions // Mod. Pathol. 2006 Mar. V. 19(3). P. 384 - 91.
- Ikeda K., Tate G., Suzuki T., Mitsuya T. Coordinate expression of cytokeratin 8 and cytokeratin 17 immunohistochemical staining in cervical intraepithelial neoplasia and cervical squamous cell carcinoma: An immunohistochemical analysis and review of the literature // Gynecol. Oncol. 2008 Jan 11.
- Tsoumpou I., Arbyn M., Kyrgiou M. et al. p16INK4a immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta - analysis // Cancer. Treatment. Reviews. 2009. V. 35 (3). P. 210 - 220.
- Lesnikova I., Lidang M., Hamilton - Dutoid S., Koch J. p16 as a diagnostic marker of cervical neoplasia: a tissue microarray study of 796 archival specimens // Diagn. Pathol. 2009. Jul. 9. V.4(1). H. 22.
- Klaes R., Friedrich T., Spitkovsky D. et al. Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri // Int. J. Cancer. 2001. V. 92. P. 276-284.
- Dray M., Russell P., Dalrymple C. et al.p16(INK4a) as a complementary marker of high - grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies // Pathology. 2005 Apr. V. 37(2). P. 112 - 24.
- Hu L., Guo M., He Z. et al. Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents. // Mod. Pathol. 2005 Feb. V. 18(2). P. 267 - 73.
- Rocha A.S., Bozzetti M.C., Kirschnick L.S., Edelweiss M.I.Antibody anti - p16(INK4a) in cervical cytology // Acta. Cytol. 2009 May - Jun. V. 53(3). P. 253 - 62.
- Pientong C., Ekalaksananan T., Kongyingyoes B. et al.Immunocytochemical staining of p16INK4a protein from conventional Pap test and its association with human papillomavirus infection //Diagn. Cytopathol. 2004. V. 31. P. 235-242.
- Agoff S.N., Lin P., Morihara J., et al. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki - 67 expression and detection of high - risk HPV types. // Mod. Pathol. 2003 Jul;16(7):665 - 73.
- Branca M., Ciotti M., Santini D. et al.p16(INK4A) expression is related to grade of cin and high - risk human papillomavirus but does not predict virus clearance after conization or disease outcome // Int. J. Gynecol. Pathol. 2004 Oct. V. 23(4). P. 354 - 65.
- Branca M., Giorgi C., Santini D.et al.Aberrant expression of VEGF - C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer // J. Clin. Pathol. 2006. V. 59(1). P. 40 - 7.
- Branca M., Ciotti M., Giorgi C. et al. Predicting High - Risk Human Papillomavirus Infection, Progression of Cervical Intraepithelial Neoplasia, and Prognosis of Cervical Cancer With a Panel of 13 Biomarkers Tested in Multivariate Modeling // Int. J. Gynecol. Pathol. 2008 Feb 27.